Clinical Trials

With trial delays costing millions daily, Spectrum Science hires Marie Emms to fuse 30 years of experience with AI—a strategic move aimed at market dominance.

Keenova Therapeutics' positive Phase 3 results for XIAFLEX could bring the first-ever approved drug for plantar fibromatosis, a painful, disabling condition.

After a clinical hold on its lead drug, Quantum BioPharma is spending heavily on marketing. Is it a bold play for survival or a sign of desperation?

A new deal to develop cancer drugs reveals a seismic shift: China is no longer just a market, but a core engine in a new global innovation network.

A new company aims to fix a multi-billion dollar problem in drug development by using advanced biomarker tests to find the right patients before they even start.

Clinical-stage Nyra Medical begins a key U.S. study for its novel mitral valve device, a strategic move challenging established players in a crowded field.

Cytokinetics is set to unveil groundbreaking data for aficamten, a therapy that could become the first-ever approved treatment for non-obstructive HCM.

As OKYO Pharma woos investors with a promising eye drug, it carries the hopes of patients with debilitating pain. A look at the science, stakes, and systems.

The FDA has fast-tracked mitapivat for sickle cell disease, offering new hope for patients. But a closer look reveals the high stakes of this strategy.

HMNC Brain Health's new oral ketamine shows promise by minimizing side effects, but an unmet endpoint raises questions. Is this the key to at-home TRD care?

With a promising osteoarthritis drug in late-stage trials, Levicept hires a CFO known for Nasdaq listings and M&A, signaling a major financial move.

Vivos Inc. wins FDA approval for a human trial of RadioGel®, a targeted therapy that could offer new hope for patients with non-resectable thyroid cancer.

With a new ADC expert as CMO, Corbus Pharmaceuticals is advancing its dual pipeline. This move signals a critical phase for its cancer drug and obesity therapy.

With a breakthrough oral drug for a rare form of blindness, Belite Bio heads to a key symposium. Can it convince investors it can win a crowded race?

IceCure's ProSense™ is reshaping oncology in Brazil. A US FDA approval provided a critical tailwind, validating a less invasive future for cancer care.

Invivyd's COVID-19 drug PEMGARDA loses its emergency status, sparking a high-stakes race for full approval and raising fears of a looming gap in patient care.

A South Korean biotech's diabetes drug finds new purpose in fighting FSHD, backed by a foundation's innovative funding model that could reshape rare disease R&D.

UK biotech Ananda Pharma advances its MRX1 drug to Phase 2 trials, targeting a debilitating chemotherapy side effect with no current effective treatment.

Immunomic Therapeutics begins human trials for ITI-9001, an saRNA vaccine aiming to rewrite the immune response to Japanese cedar pollen allergy.

Cerezen, a non-invasive device shown to reverse cognitive decline, has EU approval but remains in FDA limbo, raising questions about US patient access.